All In Biotech

Drug Trial Radar · NCT05817214

Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer

Cadonilimab Plus Anlotinib for Recurrent, Metastasis or Persistent Cervical Cancer

Last checked: Nov 19, 2026Latest source record: Apr 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Feb 16, 2023

Primary completion

Nov 30, 2025

Study completion Feb 28, 2027

Sponsor

Lead sponsor
Zhongnan HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Akeso Biopharma Co., Ltd.
First posted
Apr 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to test a new treatment combination including cadonilimab, anlotinib and granulocyte-macrophage colony-stimulating factor (GM-CSF) in recurrent, metastasis and persistent cervical cancer. The main questions it aims to answer are: * The efficacy of this combination in R/M/P CC; * The tolerance of this combination in R/M/P CC; * Possible biomarker of treatment response for this combination. Participants will receive cadonilimab of 10mg/kg every three weeks at day 1, take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break and subcutaneously injection of GM-CSF (200ug) from day 1 to day 14, then also take a 7-days break. This treatment will continue until progression or intolerable toxicity or withdraw of participants and it will last for no longer than 2 years.

Conditions

  • Cervical Cancer

Interventions

  • CadonilimabDrug

    All Participants will receive cadonilimab of 10mg/kg every three weeks at day 1

  • AnlotinibDrug

    All Participants will take anlotinib (12mg) orally in day 1 to day 14, then take a 7 days break.

  • Granulocyte-Macrophage Colony-Stimulating FactorDrug

    All Participants will have subcutaneously injection of granulocyte-macrophage colony-stimulating factor from day 1 to day 14, then take a 7 days break.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.